Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837504 | 0.95 | TRPA1 (0.36) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4840901 | 0.94 | TRPA1 (0.39) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4839596 | 0.94 | POLB (0.36) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4845391 | 0.94 | TRPA1 (0.37) | TRPA1RORCMAPK1MMP1MMP9 | |
| SCHEMBL4838813 | 0.93 | MMP8 (0.40) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4841609 | 0.92 | TRPA1 (0.36) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4845155 | 0.90 | TRPA1 (0.36) | TRPA1POLBRORCMAPK1MMP1 | |
| SCHEMBL4840464 | 0.89 | TRPA1 (0.39) | TRPA1RORCMAPK1MMP1MMP9 | |
| SCHEMBL4841283 | 0.89 | TRPA1 (0.37) | TRPA1RORCMAPK1MMP1MMP9 | |
| SCHEMBL4843296 | 0.88 | PTGER3 (0.39) | TRPA1POLBRORCMMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885POLB 4775/4885RORC 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.